By Michael King
In August, we expected a strong finish to the year for the biotech sector. Obviously, the Sept. 11 attacks have significantly altered investors’ attitudes about the market and economy. Most recently, many have remained wary as fears of a silent, stealthier weapon, against which we have little defense, have spread across the country.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.